American Well Earnings Call: Key Takeaways
Amwell is executing a turnaround focused on platform consolidation and cost discipline, significantly narrowing EBITDA losses despite revenue declines from legacy churn.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All American Well Corp filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
Amwell is executing a turnaround focused on platform consolidation and cost discipline, significantly narrowing EBITDA losses despite revenue declines from legacy churn.
For the quarter ended September 30, 2026, American Well reported revenue of $49.0 million, a decrease from $56.3 million in the prior year period. The company significantly narrowed its net loss to $11.0 million compared to $31.9 million in 2025, driven by substantial reductions in research and development and general and administrative expenses.
American Well Corp (Amwell) reported Q3 2026 total revenue of $49.0 million, exceeding its previous guidance, and a net loss of $11.0 million. The company raised its full-year 2026 revenue outlook to a range of $204-$206 million and reiterated its goal to achieve positive cash flow from operations in the fourth quarter of 2026.
“Health plans and employers want engagement, outcomes and proof, and Amwell’s single platform is built to deliver all three. Across six focus areas that all run on one platform, we are activating more members, simplifying their experience and deepening their relationship with clinicians, giving customers choice without the sprawl, demonstrating outcomes, and using a common data structure to show what works. We expect to generate positive cash flow from operations in the fourth quarter, and we believe we are well positioned to be the trusted platform where AI-powered care runs.”
Dr. Ido Schoenberg, Chairman and CEO of Amwell